Maple Leaf Green World (MGW:CA)Hi Travis, I’d really appreciate your take on Maple Leaf Green World Inc. (MGW CA) It’s a TSA penny stock based in Calgary, Alberta. Momentum on it yesterday and today is exponentially higher than normal, and the price is up 25% over two days. I only notice it because it’s on my watchlist, since I’ve […]
Articles
- Most Relevant
- Most Recent
Is anyone following this upcoming video promo?
Has anyone discovered the small battery company the stock advisors are baiting us with. I tracked down ILIKF but I am not sure this is the one they are referring to. Any thoughts?
Anyone know what this is: “Dr. Mark Skousen here. Today, I’m going to show you how to retire on a single stock… My “Alpha-Gold” investment. By this time next year, you could be enjoying 10X… 20X… even 30X your money. But only if you get into it now, before the gold rush really takes off. […]
We’ve got a quickie here that a few folks asked about, and I thought I’d throw it out for you just because there are so many of you who are interested in biotech stocks (and why wouldn’t you be, of course, given the fact that the biotech index would have given you a 350%+ return […]
Curing the blind — that sounds lovely, eh? That’s the headline of the latest ad from Patrick Cox … … we’ve seen many overpromising ads from Cox’s Breakthrough Technology Alert over the years, and they never fail to catch the attention of the great Gumshoe readership. It is, after all, just the kind of thing […]
[ed. note: Michael Jorrin, who I like to call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes about non-financial health and medical issues for us a couple times a month. Like all of our authors, he chooses his own topics and his words and opinions are his alone. Enjoy!] We’re talking […]
Dr. KSS will be reporting from the Biotech Showcase in San Francisco in the comments below. Enjoy!
It’s hard to stay away from the coronavirus pandemic, even though Doc Gumshoe basically has no information that’s any different from what’s flooding into your inboxes or TV screens or, for those of us who are still members of the ancient fellowship of newspaper readers, the pages of our daily newspapers. But a few […]
I suppose I should expect this by now — whenever Frank Curzio and the gang put out a teaser for Phase 1 Investor, which is the big-money newsletter from Stansberry & Associates ($5,000/year, though almost always “on sale” at $3,000 when they’re running promos), my inbox gushes like Spindletop. Didn’t matter if it was a […]
This article was originally published on August 4, 2022, but Ray Blanco has lately been pitching it as an urgent “last chance” idea because of their March 20, 2023 announcement, so we’re re-sharing this older article so folks can at least know what company he’s talking about (the preclinical results they announced at a conference […]
This one comes in from Stansberry and Associates, as an ad for Porter Stansberry’s Investment Advisory — if you subscribe, they’ll send you the special report: “Part D Compensation”— Monthly Checks for the Next 9 Years. Now, Stansberry and his folks love to come up with new terms and phrases to describe the investment strategies […]
This ad has been crashing in on Gumshoe beach in massive waves over the last week, so I thought it might be time to take a gander. It’s for the Xcelerated Profits report at Mt. Vernon Research — the last time I saw a similar ad it was from Karim Rahemtulla for this same report, […]
A pre-emptive tease: no newsletters are yet touting this company, but like many stocks that they do tease, it is small, cheap, almost unknown, and even has the exotic appeal of being Australian. Sort of. At Stock Gumshoe we not only deconstruct pitched stocks, we find teasable stocks before the newsletters do! Let’s return to […]
[Ed. Note: Dr. KSS writes about medical topics and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his thoughts and words are his own. Enjoy!] Here we are, solidly in the postmodern 21st century, “so late in the goddam day,” as one of novelist Martin Amis’s characters says, and what […]
What set me off on this rant was the very first comment on the piece that posted on January 31st, “Looking Backward – And a Peek in the Other Direction.” Here’s the comment: “Thanks, Doc. Hope you will comment on the news out of Israel this week: https://www.jpost.com/HEALTH-SCIENCE/A-cure-for-cancer-Israeli-scientists-say-they-think-they-found-one-578939” Naturally, I looked, and what I found […]
[Ed. note: Michael Jorrin, who we like to call “Doc Gumshoe,” is not a doctor, he is a longtime medical writer who contributes pieces for us that we hope give a good background or perspective on medical issues (and marketing) for those of us who are as overwhelmed with “live to 150” promises as we […]
[ed. note: Michael Jorrin, who I call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes for us about medicine and health a couple times a month. He has agreed to our trading and disclosure restrictions, but does not generally write directly about investment ideas. His ideas, thoughts and words are his […]
[ed note: Michael Jorrin, who I like to call “Doc Gumshoe”, is a longtime medical writer (not a doctor) who shares his thoughts with us from time to time, generally on non-financial topics in health and medicine (as today, though, he mentions a couple publicly traded companies). His words and opinions are his own.] The […]
[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, is a longtime medical writer (not a doctor) who writes for us a couple times a month about health issues, marketing, and trends. He does not typically focus on specific investment opportunities, but has agreed to our trading restrictions… as with all of our […]
This article originally appeared on June 3, it has not been updated. “If you complete and return the 2-page form sampled above, your broker could pay you $2,100 in less than 2 weeks. What’s even more incredible is that soon after you could receive an additional check for about $1,200.” That’s the latest “free money” […]
“If you complete and return the 2-page form sampled above, your broker could pay you $2,100 in less than 2 weeks. What’s even more incredible is that soon after you could receive an additional check for about $1,200.” That’s the latest “free money” tease from the folks at Stansberry & Associates — leading us into […]
I’ve written about various teasers from Mark Skousen’s services several times over the last year or so, and he is, at least, always confident. He has teased several good stocks that have performed well, including Sadia, ABB, and CVRD, and several that have stunk — like Volcano and Centerline Holdings (to be fair, I thought […]
OK, so that headline is a little bit deceiving — the ad is for Bottarelli Research Small Cap, and much of it was indeed about what they thought was the most undervalued stock in the S&P 500. But they also told us directly what it was. So we know that Bryan Bottarelli thinks that Titanium […]
This delightful ad has clearly graced many an inbox over the past few days — I know I’ve gotten it about a dozen times myself, not to mention the hundreds of Gumshoe readers who have also been kind enough to send it along. OK, dozens. Still. So the marketing push is on … … but, […]
I’ve had dozens of readers send this one along, most with a long line of question marks. The teaser has been around for a while (a couple years, as far as I can tell), but it continues to spark interest — especially with the dollar at ridiculous lows, inflation fears bubbling, and gold near $1,000 […]
Newsletters are notorious for re-using the same ad copy for years and years and years, and the Motley Fool is no different — when they get a marketing pitch that really works, they keep trotting it out again, and again, and again. I’ve mentioned this before, particularly with their “Next Berkshire Hathaway” pick that gets […]
Ah, another one from the Motley Fool! Like mother’s milk, it nourishes the Gumshoe so to pore through a ponderous Fool tome in search of clues to great stocks. Today, we’re blessed with a teaser letter for the Hidden Gems newsletter, with the letter coming from Bill Mann, who runs that newsletter in partnership with […]
OK, so leaving aside the fact that if you ever see a subject line like that in your email, you’re probably better off just deleting it, let’s take a little Gumshoe gander at the latest campaign from Toby Smith’s ChangeWave MicroCap newsletter. For those who don’t know him — and how you could avoid his […]
Continuing the rundown of the best teaser picks of the year, this one comes from the Motley Fool, specifically from their Rule Breakers newsletter, and it is the only one of the “next Google” stocks that I’ve seen teased that has gotten even close to a double so far. It reached a 141% gain that […]
This isn’t a real sleuth job, just a quick note because the email box is heating up with two competing teaser recommendations for the same stock … and the company reports earnings after the close on Wednesday, so now’s a decent time to be paying attention to it. The first recommender is Robert Hsu, whose […]
This one comes in from Andrew Mickey’s Breakaway Investor — we’ve seen a few of his ideas in the past, with mixed results. Not surprising, since a lot of the companies he likes are very small and make for some volatile investing at times. And it’s a good story, whether or not you end up […]
This one is from Chris DeHaemer at Taipan’s Red Zone profits, and it looks like it circulated pretty heavily on Friday and over the weekend. It’s for a company that uses momentum, in Dehaemer’s description, to store electrical energy, and essentially runs a big “momentum battery” that they use to buy up electricity at low […]
This one came in a day or two ago from Louis Navellier, for his Emerging Growth newsletter service. One of my readers suggested a solution, and his solution seems to be a decent guess … but let me get to the details. Navellier thankfully spares us the story of Chinese overall growth — we do […]
I’m finding that sleuthing out stock picks is a healthy way to indulge in my stock market addiction on days like this, when I would otherwise be throwing money at what look to me like serious bargains, only to watch them fall a further 10 or 20% in the minutes following my purchase. So in […]
When the Motley Fool Hidden Gems newsletter sends out a teaser email, I always pay attention — not only because I was a subscriber to that service a few years ago and generally liked the newsletter, but because it has recently ranked as the best newsletter in the country, according to Hulbert … and that’s […]
This one comes in from Stansberry and Associates, as an ad for Porter Stansberry’s Investment Advisory — if you subscribe, they’ll send you the special report: “Part D Compensation”— Monthly Checks for the Next 9 Years. Now, Stansberry and his folks love to come up with new terms and phrases to describe the investment strategies […]
Streetsifter strikes again — he sent in this solution for an email that just started circulating, and he sent it in before I had even gotten around to reading the email. He even wrote it up nicely, so most of what follows is just a minor edit of his words (I agree he’s clearly got […]
This ad comes to us from Andrew Mickey at Breakaway Investor, who we’ve heard from a few times before. The solution was suggested by a few readers, the first of whom was Randy Last-name-withheld-to protect-the-innocent, and one of them, one of the Stock Gumshoe Irregulars who wishes to remain anonymous (we’ll call him Streetsifter … […]
Hi folks — this is a submission from a reader that I haven’t yet looked at, so you can follow up for yourselves. Don’t want to delay it while I try to find time, so have at it: The email ad in question is for the Venture Insider, and you may have seen this one […]